Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Completed 7Terminated 4Recruiting 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Bites and Stings 1

Interventions

pembrolizumab 183Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 53fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 39Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Hydroxyurea × Clear all
NCT05853458 2026-04-30

HU-F-AIM

Novartis

Phase 4 Terminated
76 enrolled
Myeloid

Polycythemia Vera

NCT06063317 2026-03-06

OASIS

Imugene Limited

Phase 1 Terminated
25 enrolled

Bites and Stings

NCT03860844 2025-09-09

ISAKIDS

Sanofi

Phase 2 Terminated
67 enrolled 25 charts
LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Novartis

Phase 2 Terminated
231 enrolled 12 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡